Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixeddose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-tovery severe chronic obstructive pulmonary disease Table 2 and Fig. 3 . These errors have since been acknowledged and corrected in this erratum The first sentence in the subsection "Baseline characteristics" originally read: Patients' baseline and demographic characteristics are shown in Table 1 (mITT  population) .
Erratum
Upon Publication of the original article [1] several discrepancies were highlighted in the following sections; Results, Table 1, Table 2 and Fig. 3 . These errors have since been acknowledged and corrected in this erratum The first sentence in the subsection "Baseline characteristics" originally read: Patients' baseline and demographic characteristics are shown in Table 1 (mITT  population) . This should read: Patients' baseline and demographic characteristics are shown in Table 1 .
The header of Table 1 read: Baseline demographics (mITT population)
This should read as: Baseline demographics (ITT population) It was noticed that Table 2 contained an error. In Table 2 , data row 2, the footnote symbol 'c' was erroneously included in the third column. The footnote symbol 'c 'should be placed in the second column in this row. The corrected Table 2 is shown below.
It was noticed that in Fig. 3b , the error bar on the 4th data point (AUC inf ) was incorrectly given. The error bar on the 4th data point (AUCinf ) should range from 74.88, to 103.28 The corrected Fig. 3b is shown below.
These corrections do not change the conclusions of the article. AUC 0-inf , area under the curve from time 0 to infinity; AUC 0-12 , area under the curve from 0 to 12 h post-dose; CI, confidence interval; C max , maximum observed plasma concentration; DPI, dry powder inhaler; FF, formoterol fumarate; GFF, glycopyrrolate/ formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; PK-mITT, pharmacokinetic modified intent-to-treat
